Ascentage Pharma Group InternationalASPHF -3.51%66 Net Current Asset Value is $0.12 as of Dec. 2025, which is 100% below its 10-year median of 35.88. GuruFocus rates ASPHF with a GF Score™ of 66/100 and a GF Value™ of $7.38 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 943 Biotechnology companies, Ascentage Pharma Group International ranks worse than 93.53% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Ascentage Pharma Group International's Net Current Asset Value or its related term are showing as below:
ASPHF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.46 Med: 35.88 Max: 58.39
Current: 41.18
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Ascentage Pharma Group International was 58.39. The lowest was 9.46. And the median was 35.88.
ASPHF's Price-to-Net-Current-Asset-Value is ranked worse than 93.53% of 943
companies
in the Biotechnology industry
Industry Median: 4.95
vs ASPHF: 41.18
Ascentage Pharma Group International (OTCPK:ASPHF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Ascentage Pharma Group International Net Current Asset Value Related Terms
Ascentage Pharma Group International Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Net Current Asset Value Chart
ASPHF vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.12 mean?
Ascentage Pharma Group International (ASPHF) has a Net Current Asset Value of $0.12 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Ascentage Pharma Group International and its competitors. This is 100% below median its historical median of 35.88. Over the past decade, Ascentage Pharma Group International's Net Current Asset Value has ranged from 9.46 to 58.39. According to the industry distribution chart, Ascentage Pharma Group International ranks #882 out of 943 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Ascentage Pharma Group International's Net Current Asset Value too high?
Ascentage Pharma Group International's current Net Current Asset Value of $0.12 is 100% below median its 10-year median of 35.88. Over the past 10 years, this metric has ranged from a low of 9.46 to a high of 58.39. The Biotechnology industry median Net Current Asset Value is 4.95. Ascentage Pharma Group International's value of $0.12 is 97.6% below this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #882 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #882 out of 943 companies for Net Current Asset Value. This places Ascentage Pharma Group International in the lower half of its industry. The industry median Net Current Asset Value is 4.95. Ascentage Pharma Group International's value of $0.12 is 97.6% below this benchmark. Historically, Ascentage Pharma Group International's own Net Current Asset Value has ranged from 9.46 to 58.39 over the past decade. While the company's 10-year median is 35.88 vs. the industry median of 4.95, Ascentage Pharma Group International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.95, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Net Current Asset Value of $0.12 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Net Current Asset Value is $0.12, which is 100% below median its own 10-year median of 35.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.38, compared to a current price of $4.53 — trading 38.6% below its estimated fair value. The current Net Current Asset Value is $0.12, which is 100% below median its 10-year median of 35.88 and 97.6% below the Biotechnology industry median of 4.95. Ascentage Pharma Group International's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Net Current Asset Value is $0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 38.6% below its estimated GF Value™ of $7.38.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Net Current Asset Value: $0.12 (100% below median its 10-year median of 35.88)
GF Value™: $7.38 vs. price of $4.53 (38.6% below fair value)
Industry Position: 97.6% below the Biotechnology median (#882 of 943)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
66GF Score
Get the complete analysis for ASPHF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
